Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at HCA's multiple
Needs Annual EPS is negative, HCA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
SUPERNUS PHARMACEUTICALS, INC.
HCA vs SUPN
CATALYST PHARMACEUTICALS, INC.
HCA vs CPRX
Harmony Biosciences Holdings, Inc.
HCA vs HRMY
ELI LILLY & Co
HCA vs LLY
INCYTE CORP
HCA vs INCY
Sarepta Therapeutics, Inc.
HCA vs SRPT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA can sustain its current profitability and continue converting revenue into earnings at roughly current margins, then a selective long bias is reasonable because HCA trades below the implied P/S value and below the low end of the DCF range; however, the case is only moderate because the provided upside is 19.2% and several quality metrics are unavailable.
On the provided P/S framework, HCA appears to trade below its implied value, with a current price of $402.59 versus an implied price of $479.78, suggesting 19.2% upside. HCA also sits inside the broader valuation ranges shown, trading below the DCF range and near the lower half of the historical band, while VNDA’s weak operating profile makes it a poor direct quality anchor for valuation comparison.
Supporting Metrics
